A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers
机构：[1]Xuanwu Capital Hosp Med Univ, Beijing, Peoples R China首都医科大学宣武医院[2]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China[3]Xuanwu Hosp, Dept Hematol, Beijing, Peoples R China首都医科大学宣武医院
第一作者机构：[1]Xuanwu Capital Hosp Med Univ, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Hu Chaoying,Li Jian,Sun Wanling,et al.A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers[J].BLOOD.2022,140:2447-2448.doi:10.1182/blood-2022-156195.
APA：
Hu, Chaoying,Li, Jian,Sun, Wanling&Zhang, Lan.(2022).A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers.BLOOD,140,
MLA：
Hu, Chaoying,et al."A First-in-Human Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Polyethylene Glycol-Erythropoietin Injection, RD01, in Healthy Volunteers".BLOOD 140.(2022):2447-2448
医学